Conservative hysteroscopic treatment of stage I well differentiated endometrial cancer in patients with high surgical risk: a pilot study

J Gynecol Oncol. 2019 Jul;30(4):e62. doi: 10.3802/jgo.2019.30.e62. Epub 2019 Apr 22.

Abstract

Objective: To report hysteroscopic treatment combined with levonorgestrel-releasing intrauterine device (LNG-IUD) to treat women with early well differentiated endometrial cancer (EC) at high surgical risk.

Methods: Nine women diagnosed with stage IA, grade 1 endometrioid EC which was contraindicated or refused standard treatment with external beam radiation therapy with or without brachytherapy were enrolled in our prospective study. Endo-myometrial hysteroscopic resection of the whole uterine cavity and the placement of LNG-IUD for 5 years was performed. Response rate, perioperative complications, and recurrence of disease were evaluated.

Results: None had intra or post-operative complications and all were discharged no later than the third day of hospitalization. After 6 months from surgery, all the women showed a complete regression of the lesion. All the women completed the 5 years follow-up and in no case was detected sign of recurrence. Two women died for causes unrelated to the tumor or the ongoing therapy.

Conclusion: The alternative treatment with endo-myometrial hysteroscopic resection and LNG-IUD in women with stage IA, grade 1 endometrioid EC showed initial encouraging outcomes in terms of effectiveness and safety.

Keywords: Endometrial Cancer; High Surgical Risk; Hysteroscopic Surgery; Obesity.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Carcinoma, Endometrioid / pathology
  • Carcinoma, Endometrioid / therapy*
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy*
  • Female
  • Humans
  • Hysteroscopy / methods*
  • Intrauterine Devices, Medicated
  • Levonorgestrel / administration & dosage*
  • Longitudinal Studies
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Levonorgestrel